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high level of commitment that
higher education institutions have
to their business partners. The
report shows a marked cultural
change in UK universities over
the past decade, and that most
of them are actively seeking to
play a broader role in the regional
and national economies.”
Information from a wide range
of knowledge-transfer activities,
including licensing of technology,
support for regional regeneration,
provision or professional training
courses and consultancy, has
been gathered by the report. The
public sector was found to be the
highest-priority business area,
replacing the information
technology industry, which held
this position in the previous
survey. The cultural and creative
sectors also scored highly.
Lord Sainsbury, the science
minister said: “UK universities
have risen to the challenge of
transferring their knowledge to
industry and are becoming
increasingly entrepreneurial.
Their pioneering work is being
turned into practical applications
and is making a valuable
contribution to the economy and
society.”
In 2001, the government
announced the allocation of £120
million to over 200 universities,
colleges and hospitals to enable
them to exploit their research.
An additional £171 million was
allocated through the Higher
Education Innovation Fund (HEIF)
after the 2002 government
spending review to support
knowledge transfer in higher
education institutions. Further
grants will be made later this
year.
Treasury officials are
considering proposals in the
Lambert report to boost the HEIF
budget and to create a £200
million scheme for business-
oriented research in universities.
Alan Johnson, higher education
minister, said, “We have always
maintained our commitment to
encouraging effective
university–business
collaboration. The increased
resources we are providing
through the HEIF will go a long
way towards boosting and
increasing this work.”
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What turned you on to biology in
the first place? Actually,
chemistry. When I was an
undergraduate at the University of
Virginia in the early 70s, I took a
single introductory class in biology
that left me with the (false!)
impression that the field was
descriptive and not yet ready for
the application of physical
sciences. In contrast, my organic
chemistry professors were
electrifying and left me feeling that
organic chemistry was at the
center of the Universe, a belief that
energized me throughout my
graduate studies at Harvard. My
horizons were dramatically
expanded at Yale, where I was an
assistant professor, after attending
lectures by Aaron Klug and Eric
Kandel. It was only then that I even
started reading about modern
biology. 
But the transforming event
followed the synthesis, by the first
graduate student to join my lab,
Conrad Santini, of periplanone-B, a
sex pheromone of the American
cockroach Periplaneta americana.
Conrad and I searched the bowels
of the Yale Chemistry Department
to locate a female cockroach.
Puffing attomolar solutions of
periplanone-B in the vicinity of the
insect caused a physiologic
response that was breathtaking!
(With Michael Lerner, we also
measured an electrophysiological
output on an oscilloscope following
a puff of the synthetic pheromone
onto a dissected cockroach
antennae grasped with an alligator
clip, a demonstration I offered to
undergraduate students enrolled in
my organic chemistry course.)
It was then that I knew my
mission in life. A small molecule
that induces such amazing effects
should serve as a powerful probe.
The next twenty years have been
spent exploring biology with small
molecules. 
Were you at a disadvantage,
without proper training in
biology? Yes and no. Biology is an
exceedingly complex subject, and I
doubt that I will ever feel as though
I am a true biologist. But chemistry
gave me the skill sets of molecule
building (‘organic synthesis’) and
quantitative analysis. As biology
evolves to an increasingly
quantitative science, these
chemical skills are becoming even
more useful.
Hasn’t chemistry long been
viewed as a field connected to
medicine? Yes, but gratifyingly it
is also becoming viewed as a field
connected to biology, as
evidenced by the increasing
popularity of the term ‘chemical
biology’.
Is it true that funding agencies
are considering supporting
efforts to initiate drug discovery
efforts in academic chemistry
and biology labs? Yes, but not
drug discovery efforts as known in
the pharmaceutical industry. I think
the concept is to do something in
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parallel, something complementary
to what takes place in pharma.
How so? The emergence of
chemical biology in universities
and medical schools reflects a
transition towards the integration
of small molecule synthesis, small
molecule screens and informatics
with the goal of illuminating
principles that underlie biology and
disease. This is not drug discovery,
but the resulting concepts and
technologies can be incorporated
by the pharmaceutical industry into
their drug discovery process. For
example, such efforts have already
identified many previously
unrecognized therapeutic targets
whose activities can be modulated
by small molecules — information
that can be exploited by the
pharmaceutical industry.
Will the ‘gulf’ between chemists
and biologists, to which Arthur
Kornberg famously referred,
interfere with these ambitions?
Possibly, as so much still needs to
be accomplished and the gulf still
exists. To advance our
understanding of disease biology,
we need chemists to populate
‘chemical descriptor space’
beyond that occupied traditionally
by drugs, yielding diverse small
molecules that disrupt
protein–protein interactions,
enhance binding specificity, and
modulate targets previously
thought to be ‘non-druggable’. We
need to unleash the awesome
creativity of biologists in a disease-
relevant and small molecule-based
context. But creating a social
structure where chemists are eager
to use their skills to follow-up on
biologists’ discoveries is vitally
important. The participation of
chemists prior to the start of the
screening process develops an
environment in which the chemists
are excited to participate with
biologists in efforts to optimize the
properties of the hits discovered in
screens, thereby moving them
towards more effective disease
probes or even drugs. 
Any other relevant sociologic
issues? I think so. For example,
there are operational and cultural
issues that distinguish academic
research from research performed
in the pharma industry.
Operationally, academic biologists
tend to tinker with candidate
assays, a trial-and-error process
that requires ready, hands-on
access to a minimal set of
screening equipment and
expertise. Much of the work is
performed in a pilot mode, rather
than the large-scale but more
limited-in-scope mode often used
in industry. Culturally, academic
biologists are more apt to create
new screening paradigms than to
adopt those used in drug discovery
in industry. Examples include the
use of matrix screening datasets to
create signatures of cell states, and
the use of state-switching assays.
Academic screening centers differ
from their industrial counterparts.
Is this another example of ‘big’
biology? Not really. Biology in all
sizes benefits from the tools and
concepts being developed by
chemical biology, just as all sizes
of biology labs have benefited from
DNA sequencing efforts. Some
projects are best done on a large
scale, while others are best done
on a small scale.
With so many hurdles to over-
come, are there reasons to be
optimistic? Certainly. Biologists
are moving to a more quantitative
mindset with which chemists are
inherently comfortable. Chemists’
exposure to more biology-driven
projects is providing a vehicle to
explore new facets of our field. The
fearless young generation appears
eager to bridge not only the gulf
between biology and chemistry,
but also those between biology
and mathematics, computer
science and other physical
sciences. They are our source of
great hope.
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Claudins
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What are they? Claudins are a
24-gene family of integral
membrane proteins. Members of
the claudin family range in size
from 20 to 27 kDa and are
predicted to have four
transmembrane-spanning
domains with cytoplasmic amino
and carboxyl termini. The carboxyl
termini of some claudins interact
with PDZ-domain-containing
peripheral membrane proteins and
other cytoplasmic proteins. The
manner of lateral and apposing
membrane (claudin–claudin) and
other (claudin–X) interactions,
combinatorial aspects, and
stoichiometry have yet to be
determined.
Where do they localize?
Claudins are found in the tight
junction at the interface of the
basolateral and apical membranes
of polarized epithelial and
endothelial cells, and also at
paranodes in compact myelin.
Transfected claudins are capable
of forming tight junction ‘strands’
or ‘fibrils’, the freeze–fracture
descriptions of a branching and
anastomosing network of rows of
intramembranous particles
characteristic of tight junctions.
Claudins are also found in the
basolateral membranes, possibly
as precursors to the fibrils. 
What do they do? The
extracellular domains of claudins
in one cell are thought to interact
with those in an apposing cell to
form a new class of ion channel
(see Figure 1). These channels
confer ion selectivity to the
paracellular pathway between
luminal and basolateral
extracellular compartments. The
permeability properties of the
paracellular pathway have the
biophysical characteristics of
conventional ion channels,
including ion selectivity,
anomalous mole fraction effects,
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